Testing a new radioactive treatment for advanced neuroendocrine cancers

This trial is testing a new radioactive medication called [225Ac]Ac-ETN029 in patients with advanced neuroendocrine cancers—including small cell lung cancer, large cell lung cancer, prostate cancer, and pancreatic cancers. The medication is designed to find and attack cancer cells that have a specific protein called DLL3 on their surface. This is an early-stage study (Phase I) that will help doctors understand whether the treatment is safe and how well it works.

Neuroendocrine cancers are aggressive and often don't respond well to standard treatments. Researchers believe that by using a radioactive medication that targets a specific protein found on these cancer cells, they may be able to deliver radiation directly to tumors while sparing healthy tissue, potentially offering a new treatment option for patients who have limited choices.